| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910777380903321 |
|
|
Titolo |
Adheremce to long-term therapies [[electronic resource] ] : evidence for action / / edited by Eduardo Sabate |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Geneva, : World Health Organization, 2003 |
|
|
|
|
|
|
|
ISBN |
|
1-280-04123-4 |
9786610041237 |
1-4175-2627-0 |
92-4-068004-7 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (206 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
|
|
Soggetti |
|
Chronic diseases - Treatment |
Patient compliance |
Medical policy |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di contenuto |
|
Contents; Preface; Ackowledgement; Scientific writers; Introduction; Take-home messages; Section I - Setting the scene; Section II - Improving adherence rates: guidance for countries; Section III - Disease-specific reviews; Annexes; Where to find a copy of this book |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Adherence to therapies is a primary determinant of treatment success. Poor adherence attenuates optimum clinical benefits and therefore reduces the overall effectiveness of health systems. ''Medicines will not work if you do not take them''. Medicines will not be effective if patients do not follow prescribed treatment, yet in developed countries only 50% of patients who suffer from chronic diseases adhere to treatment recommendations. In developing countries, when taken together with poor access to health care, lack of appropriate diagnosis and limited access to medicines, poor adherence is t |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910557380603321 |
|
|
Autore |
Morabito Alessandro |
|
|
Titolo |
Small Cell Lung Cancer: A New Era Is Beginning? |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
|
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (150 p.) |
|
|
|
|
|
|
Soggetti |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Sommario/riassunto |
|
Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody-drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques. |
|
|
|
|
|
|
|
| |